Please login to the form below

Not currently logged in

Ashfield Answers

Strategic counsel for a global healthcare sector in an ever-present state of flux

The Ashfield Answers blog features considered thoughts on, and analysis of, pharma’s strategic challenges from senior, experienced executives from Ashfield Commercial & Medical Services.

The company is a division of UDG Healthcare and a global leader in the provision of contract service solutions to pharmaceutical manufacturers, delivering local and international expertise from 22 companies in 23 countries worldwide.

Ashfield has operations in major markets including Continental Europe, the UK, North America and a presence in South America and Asia. Its growth strategy includes plans to expand into the emerging markets, Africa and Australia.

Ashfield Commercial & Medical Services focuses on supporting healthcare professionals and patients at all stages of the product life cycle.

Collectively, it provides sales teams, tele-sales, market research, business intelligence, market access, nurse educators, medical information, pharmacovigilance, medical communications and event management to healthcare companies in the international pharmaceutical market.

Featured jobs

Subscribe to our email news alerts


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...